Iobenguane sulfate I 123

Iobenguane sulfate I 123 Uses, Dosage, Side Effects, Food Interaction and all others data.

Iobenguane sulfate I 123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

Iobenguane I-123 is taken up by and stored in adrenergic nerve terminals allowing for the radiographic imaging of adrenergically inervated organs and tissues [FDA Label].

Table Of contents

• Iobenguane sulfate I 123
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Iobenguane sulfate I 123
Generic	Iobenguane sulfate I-123
Iobenguane sulfate I-123 Other Names	Iobenguane sulfate I 123
Type
Formula	C16H22I2N6O4S
Weight	Average: 640.26 Monoisotopic: 639.953520274
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

For use in the diagnostic imaging of adrenergically inervated tissues for the purposes of detecting metastatic pheochromocytoma or neuroblastoma [FDA Label]. Also used to assess the sympathetic inervation of the myocardium via determination of the heart to mediastinum ratio of radioactivity in patients with New York Heart Association class II or III heart failure.

Iobenguane sulfate I 123 is also used to associated treatment for these conditions: Neuroblastomas, Pheochromocytomas, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)

How Iobenguane sulfate I 123 works

Iobenguane I-123 is transported into adrenergic nerve terminals via the noradrenaline uptake transporter [FDA Label]. It is rapidly cleared from systemic circulation and collected in adrenergically invervated tissues. This allows for gamma-scintigraphic imaging of these tissues and their associated organs for diagnostic purposes.

Toxicity

As a radiopharmaceutical, iobenguane I-123 carries the risk of radiation toxicity if administered in innappropriately large doses or in patients with renal insufficency [FDA Label]. Fequent voiding of the bladder is encouraged to minimize the radiation dose to the bladder.

Food Interaction

No interactions found.

Elimination Route

Primarily eliminated via the urine as the parent compound (70-90%) [FDA Label]. A small amount is eliminated in the urine as m-iodohippuric acid (</10%) and free radioiodide (</6%). Less than 1% is eliminated in the feces. Iobenguane I-123 is initially rapidly cleared from circulation follwed by a slow clearance from other tissues over 4 days. Retention is the longest in highly adrenergically inervated tissues like the adrenal medulla, heart, and salivary glands. Iobenguane I-123 is not cleared by dialysis.

Innovators Monograph

You find simplified version here Iobenguane sulfate I 123